Natera (NTRA) Financial Analysis & Valuation | Quarter Chart
Natera (NTRA)
NTRAPrice: $203.19
Fair Value: 🔒
🔒score
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single... more
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwid... more
Description
Shares
| Market Cap | $29.10B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Steven Leonard Chapman |
| IPO Date | 2015-07-01 | CAGR | 0.48% |
| Employees | 4,424 | Website | www.natera.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
NTRA chart loading...
Fundamentals
Technicals
| Enterprise Value | $27.45B | P/E Ratio | — |
| Forward P/E | -1247.58 | PEG Ratio | — |
| P/S Ratio | 11.64 | P/B Ratio | 16.21 |
| P/CF Ratio | 136.25 | P/FCF Ratio | 316.27 |
| EPS | $-1.63 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 36.59% | Gross Margin | 0.65% |
| Operating Margin | -0.13% | Profit Margin | -0.09% |
| ROE | -0.15% | ROA | -0.09% |
| ROCE | -0.16% | Current Ratio | 2.96 |
| Quick Ratio | 2.83 | Cash Ratio | 1.95 |
| Debt/Equity | 0.14 | Interest Coverage | -38.93 |
| Altman Z Score | 20.34 | Piotroski Score | 4 |